×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Immunotherapy

Brielle Urciuoli
Recently, the Cancer Support Community (CSC) conducted a survey to better grasp the challenges that patients, caregivers and clinical staff members face regarding immunotherapy. The goal is to ultimately use that information to craft an empowerment program that will improve the patient experience.
Ghassan K. Abou-Alfa, MD, shares his excitement over the use of immunotherapy for liver cancer in 2018, and highlights research initiatives that are studying its potential in combination with other therapies.
Ghassan K. Abou-Alfa, MD, advises patients on what to expect from treatment with immunotherapy, including how your doctor monitors treatment response and manages adverse effects.
Ghassan K. Abou-Alfa, MD, explains how immunotherapy works in liver cancer and discusses the patient and disease characteristics that determine who is most likely to respond.
Ghassan K. Abou-Alfa, MD, highlights novel treatment approaches, such as immunotherapy, that are used in patients whose liver cancer has spread.
Ghassan K. Abou-Alfa, MD, discusses the challenges associated with treating liver cancer and highlights the various therapies used in the management of the disease.
Kristie L. Kahl
To help educate patients and enable health care teams to effectively manage these side effects, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.
Brielle Urciuoli
Researchers from Israel, the United Kingdom (UK) and Canada sought to determine the cost-effectiveness of Keytruda for the second-line treatment of patients with advanced bladder cancer. Drug costs were compared between the US, UK, Canada and Australia.
Brielle Urciuoli
Now that a number of immunotherapy agents have been approved in the bladder cancer space, identifying and managing the toxicities that may come along with them is critical.
Brielle Urciuoli
Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients. 
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable